Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06ESC
|
||||
| Former ID |
DNC008609
|
||||
| Drug Name |
YGGWL-NH2
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C30H39N7O6
|
||||
| Canonical SMILES |
CC(C)CC(C(=O)N)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)CNC(=O)<br />CNC(=O)C(CC3=CC=C(C=C3)O)N
|
||||
| InChI |
1S/C30H39N7O6/c1-17(2)11-24(28(32)41)37-30(43)25(13-19-14-33-23-6-4-3-5-21(19)23)36-27(40)16-34-26(39)15-35-29(42)22(31)12-18-7-9-20(38)10-8-18/h3-10,14,17,22,24-25,33,38H,11-13,15-16,31H2,1-2H3,(H2,32,41)(H,34,39)(H,35,42)(H,36,40)(H,37,43)/t22-,24-,25-/m0/s1
|
||||
| InChIKey |
GNLQCAGQAYEHAM-HVCNVCAESA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.